Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, China.
Cancer Lett. 2013 Apr 30;331(1):105-14. doi: 10.1016/j.canlet.2012.12.008. Epub 2012 Dec 20.
Previous studies have demonstrated the involvement of transcriptional factor forkhead box M1 (FoxM1) in cellular senescence of hepatocellular carcinoma (HCC). In the present study, we revealed that oxaliplatin could induce senescence in HCC cells, since advanced HCC patients with lower expression of FoxM1 were more sensitive to oxaliplatin therapy. Our data indicated that due to the repression by p53, FoxM1 played a critical role in oxaliplatin-induced senescence via regulating cycle-related proteins p21, p27, cyclins B1 and D1. Furthermore, inhibition of FoxM1, combined with oxaliplatin treatment, could significantly promote the senescence of HCC cells. Taken together, our findings suggest that FoxM1 may represent a promising therapeutic target for the medication of the chemosensitivity to oxaliplatin in HCC patients.
先前的研究表明,转录因子叉头框 M1(FoxM1)参与了肝癌(HCC)的细胞衰老。在本研究中,我们揭示了奥沙利铂可以诱导 HCC 细胞衰老,因为 FoxM1 表达较低的晚期 HCC 患者对奥沙利铂治疗更敏感。我们的数据表明,由于受到 p53 的抑制,FoxM1 通过调节周期相关蛋白 p21、p27、细胞周期蛋白 B1 和 D1 在奥沙利铂诱导的衰老中发挥关键作用。此外,抑制 FoxM1 联合奥沙利铂治疗可显著促进 HCC 细胞衰老。综上所述,我们的研究结果表明,FoxM1 可能成为提高 HCC 患者对奥沙利铂化疗敏感性的有前途的治疗靶点。